1. Lísek, 2003 Corticosteroids Slíva, M.D.

2. Lísek, 2003 ADRENOCORTICOSTEROIDS GLUCOCORTICOIDS MINERALOCORTICOIDS SEXUAL HORMONS Lísek, 2003

3. ADRENOCORTICOSTEROIDS Hypothalamus Adenohypophysis Suprarenal cortex trauma emotion diurnal rhythm corticosteroids ACTH CRF negative feedback Lísek, 2003

4. A. Clinical uses Substitutional therapy suprarenal insuficiency Non-endocrine diseases arthritis vascular disorders eye diseases gastrointestinal diseases blood disorders sarcoidosis immunosuppression infections (suppression of inflammation) mountain sickness nervous system disorders (MS) diseases of skin, kidney etc. Lísek, 2003

5. Daily production of corticosteroids: Lísek, 2003

6. 1. Corticosteroids bind to glucocorticoid or mineralocorticoid receptors, the steroid-receptor complex then regulates gene transcription. 2. Example for anti-inflammatory properties: glucocorticoids increase lipocortin transcription lipocortin inhibits phospholipase A decreased arachadonic acid and eicosanoids B. Mechanism of action: Lísek, 2003

7. Mechanism of action:

8. Lísek, 2003 C. Effects of glucocorticoids  liver deposits of glykogen  gluconeogenesis  catabolism of proteins  catabolism of bones  inflammatory response  immune response Lísek, 2003

9. Fluoride CH3-methyl group (  antiinflam. úč.) (  retence sodíku) D. Structure-activity relationship: - required for activity: ketone at position 3 & double bounds at 4-5 Smaller modifications in the basic corticosteroid structure alter: sodium-retaining potency antiinflammatory potency drug half-life transcortin binding Lísek, 2003

10. E. Therapeutic potential of various corticosteroids (in comparisson to hydrocortisone): Lísek, 2003

11. Glucocorticoid potencies : very high high very low dexamethasone prednisolon fludrocortisone triamcinolone methylprednisolone betamethasone Mineralocorticoid potencies: very high low very low fludrocortisoneprednisolonedexamethasone methylprednisolonebetamethasone triamcinolone Lísek, 2003 E. Therapeutic potential of various corticosteroids (in comparisson to hydrocortisone):

12. Lísek, 2003 F. Pharmacokinetics 1. Routes of administration: - oral (systemic, long-term treatment - i.m., i.v. (emergency) - topical (eyes, skin, HEENT) - intra-articular injection - inhalation - nosespray systemic local Lísek, 2003

13. 2. Metabolism of corticosteroids (liver): - reduction of double bound at 4-5 position yield to inactive forms - conjugation of inactive metabolism - excretion Liver disease affects steroid metabolis: prednisone (inactive) prednisolone (active) Lísek, 2003 F. Pharmacokinetics

14. Lísek, 2003 3. Half-lives of various corticosteroids : Lísek, 2003 F. Pharmacokinetics

15. Lísek, 2003 G. Adverse effects & toxicity: 1. General considerations: - route of administration - systemic x local - dose - length of therapy 2. Short-term systemic therapy: - no ADRs Lísek, 2003

16. 3. Long-term systemic administration: - Cushingoid features (fat redistribution) - Sodium retetion (edema, hypertension, heart failure) - Potassium loss (muscle weakness) - Glucose intolerance - Weight gain - Loss of skin collagen => skin atrophy, stria - Osteoporosis - Peptic ulcer - HPA axis suppression - CNS effects (psychosis, insomnia, nervousness, euphoria depression) - Susceptibility to infection - triamcinolone – weight loss and sedatione - Masking of symptoms of other diseases Lísek, 2003 G. Adverse effects & toxicity:

17. Lísek, 2003 4. Local use: - inhaled steroids - candidal infection, dysphonia - nasal steroids – irritation, headache, nosebleed, dry nose - topical - epidermal atrophy, steroidal acne akné, teleangiectasis, hypertrichosis, pigmentation disorders, dermatitis perioralis, granuloma gluteale infantum Lísek, 2003 G. Adverse effects & toxicity:

18. Lísek, 2003 5. Minimizing side effects: - Smallest possible dose - Shortest possible duration - Local application - Alternate day therapy - Descendent therapy during withdrawal - Encapsulation into liposomes Lísek, 2003 G. Adverse effects & toxicity:

19. Lísek, 2003 H. Corticosteroid withdrawal: 1. General consideration - dose - duration - half-life 2. Withdrawal - administration of short or intermediating-acting steroids - gradually taper dose Lísek, 2003

20. 3. Withdrawal symptoms: - acute adrenal insufficiency - dependence - exacerbation of underlying disease - re-bound phenomenon Lísek, 2003 H. Corticosteroid withdrawal:

21. Lísek, 2003 I. Drug interactions: Drugs that decrease steroid effectiveness: inductors of liver enzymes cholestyramine Drugs that increase steroid effectiveness: ATB - erythromycin oral contraceptives ketoconazole Lísek, 2003

22. Drugs affected by steroid administration: anticoagulants (dosage increase needed) antihypertensives (dosage increase needed) hypoglycemics (dosage increase needed) sympathomimetics (dosage decrease needed) Lísek, 2003 I. Drug interactions: